Keywords
Last Name
Institution

Joseph L Kuti PharmD

TitleAssociate Director, Clinical and Economic Studies
InstitutionHartford Hospital
DepartmentCenter for Anti-Infective Research and Development
Address80 Seymour Street
Phone860-545-3612
Fax860-545-3992
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Grupper M, Kuti JL, Nicolau DP. Continuous and Prolonged Intravenous ß-Lactam Dosing: Implications for the Clinical Laboratory. Clin Microbiol Rev. 2016 Oct; 29(4):759-72. PMID: 27413094.
      View in: PubMed
    2. Kuti JL, Nicolau DP. Stability of Ertapenem 100 mg/mL at Room Temperature. Can J Hosp Pharm. 2016 May-Jun; 69(3):256-9. PMID: 27403009.
      View in: PubMed
    3. Heil EL, Kuti JL, Bearden DT, Gallagher JC. The Essential Role of Pharmacists in Antimicrobial Stewardship. Infect Control Hosp Epidemiol. 2016 Jul; 37(7):753-4. PMID: 27072411.
      View in: PubMed
    4. Ghazi IM, Nicolau DP, Nailor MD, Aslanzadeh J, Ross JW, Kuti JL. Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection. Infect Control Hosp Epidemiol. 2016 May; 37(5):583-9. PMID: 26832841.
      View in: PubMed
    5. So W, Kuti JL, Shepard A, Nugent J, Nicolau DP. Tissue penetration and exposure of cefepime in patients with diabetic foot infections. Int J Antimicrob Agents. 2016 Mar; 47(3):247-8. PMID: 26897754.
      View in: PubMed
    6. Monogue ML, Kuti JL, Nicolau DP. Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance. Expert Rev Clin Pharmacol. 2016 Mar; 9(3):459-76. PMID: 26678036.
      View in: PubMed
    7. Rhodes NJ, Kuti JL, Nicolau DP, Neely MN, Nicasio AM, Scheetz MH. An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. J Infect Chemother. 2016 Feb; 22(2):78-83. PMID: 26712584.
      View in: PubMed
    8. Rhodes NJ, Kuti JL, Nicolau DP, Van Wart S, Nicasio AM, Liu J, Lee BJ, Neely MN, Scheetz MH. Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. Antimicrob Agents Chemother. 2015; 60(3):1401-10. PMID: 26666929.
      View in: PubMed
    9. Hamada Y, Kuti JL, Nicolau DP. In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure. Antimicrob Agents Chemother. 2015; 60(2):955-61. PMID: 26621619.
      View in: PubMed
    10. Housman ST, Thabit AK, Kuti JL, Quintiliani R, Nicolau DP. Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. Infect Control Hosp Epidemiol. 2016 Feb; 37(2):215-8. PMID: 26592763.
      View in: PubMed
    11. Thabit AK, Nicolau DP, Kuti JL. In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure. Antimicrob Agents Chemother. 2015; 60(1):222-8. PMID: 26482306.
      View in: PubMed
    12. Furtado GH, Cardinal L, Macedo RS, Silva JO, Medeiros EA, Kuti JL, Nicolau DP. Pharmacokinetic/pharmacodynamic target attainment of intravenous ß-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital. Rev Soc Bras Med Trop. 2015 Oct; 48(5):539-45. PMID: 26516962.
      View in: PubMed
    13. Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP, Kuti JL. Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. J Antimicrob Chemother. 2016 Jan; 71(1):189-95. PMID: 26416780.
      View in: PubMed
    14. Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP. Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis. Diagn Microbiol Infect Dis. 2015 Sep; 83(1):53-5. PMID: 26003469.
      View in: PubMed
    15. Hamada Y, Kuti JL, Nicolau DP. Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. J Antimicrob Chemother. 2015 Jul; 70(7):2064-7. PMID: 25802284.
      View in: PubMed
    16. Kuti JL, Nicolau DP. Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. Int J Antimicrob Agents. 2015 May; 45(5):512-8. PMID: 25726443.
      View in: PubMed
    17. So W, Kuti JL, Nicolau DP. Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). Infect Dis Ther. 2014 Dec; 3(2):269-79. PMID: 25410773.
      View in: PubMed
    18. Cies JJ, Jain J, Kuti JL. Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia. Pediatr Blood Cancer. 2015 Mar; 62(3):477-82. PMID: 25328131.
      View in: PubMed
    19. MacVane SH, So W, Nicolau DP, Kuti JL. In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2014 Dec; 58(12):7520-6. PMID: 25288076; PMCID: PMC4249498.
    20. Blanchette LM, Kuti JL, Nicolau DP, Nailor MD. Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae. Scand J Infect Dis. 2014 Nov; 46(11):803-8. PMID: 25262922.
      View in: PubMed
    21. Jain JG, Sutherland C, Nicolau DP, Kuti JL. Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and -20 °C. Am J Health Syst Pharm. 2014 Sep 1; 71(17):1480-4. PMID: 25147172.
      View in: PubMed
    22. Rhodes NJ, MacVane SH, Kuti JL, Scheetz MH. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. Clin Infect Dis. 2014 Sep 15; 59(6):905-7. PMID: 24867788.
      View in: PubMed
    23. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014 Jun; 14(6):498-509. PMID: 24768475; PMCID: PMC4181663.
    24. Cies JJ, Shankar V, Schlichting C, Kuti JL. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children. Pediatr Infect Dis J. 2014 Feb; 33(2):168-73. PMID: 23907263.
      View in: PubMed
    25. MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014; 58(3):1359-64. PMID: 24342637; PMCID: PMC3957877.
    26. Hagihara M, Housman ST, Nicolau DP, Kuti JL. In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2014; 58(2):874-9. PMID: 24277022; PMCID: PMC3910875.
    27. MacVane SH, Kuti JL, Nicolau DP. Prolonging ß-lactam infusion: a review of the rationale and evidence, and guidance for implementation. Int J Antimicrob Agents. 2014 Feb; 43(2):105-13. PMID: 24359838.
      View in: PubMed
    28. Bhalodi AA, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. Antimicrob Agents Chemother. 2014; 58(2):672-7. PMID: 24217694; PMCID: PMC3910832.
    29. Beaulac KR, Nailor MD, Nicolau DP, Kuti JL. The authors reply. Crit Care Med. 2013 Oct; 41(10):e298. PMID: 24060802.
      View in: PubMed
    30. Raman K, Nailor MD, Nicolau DP, Aslanzadeh J, Nadeau M, Kuti JL. Early antibiotic discontinuation in patients with clinically suspected ventilator-associated pneumonia and negative quantitative bronchoscopy cultures. Crit Care Med. 2013 Jul; 41(7):1656-63. PMID: 23528805.
      View in: PubMed
    31. Housman ST, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2013 Oct; 68(10):2296-304. PMID: 23710070.
      View in: PubMed
    32. Bhalodi AA, Keel RA, Quintiliani R, Lodise TP, Nicolau DP, Kuti JL. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit. Ann Pharmacother. 2013 May; 47(5):617-27. PMID: 23585647.
      View in: PubMed
    33. Wiskirchen DE, Housman ST, Quintiliani R, Nicolau DP, Kuti JL. Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Pharmacotherapy. 2013 Mar; 33(3):266-74. PMID: 23400916.
      View in: PubMed
    34. Bhalodi AA, Papasavas PK, Tishler DS, Nicolau DP, Kuti JL. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother. 2013 Mar; 57(3):1144-9. PMID: 23254421; PMCID: PMC3591894.
    35. Stein GE, Kulhanek G, Smith CL, Kuti JL, Nicolau DP, Scharmen A, Farnum C, Tran M, Kalra A, Havlichek DH. Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia. Ann Pharmacother. 2012 Oct; 46(10):1281-6. PMID: 23012385.
      View in: PubMed
    36. Wilde AM, Nailor MD, Nicolau DP, Kuti JL. Inappropriate antibiotic use due to decreased compliance with a ventilator-associated pneumonia computerized clinical pathway: implications for continuing education and prospective feedback. Pharmacotherapy. 2012 Aug; 32(8):755-63. PMID: 23307523.
      View in: PubMed
    37. Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, Kuti JL, Nicolau DP. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012 May; 56(5):2627-34. PMID: 22330925; PMCID: PMC3346604.
    38. Hagihara M, Kuti JL, Nicolau DP. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2012 Mar; 72(3):258-62. PMID: 22209563.
      View in: PubMed
    39. Housman ST, Tessier PR, Nicolau DP, Kuti JL. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration. Am J Health Syst Pharm. 2011 Dec 1; 68(23):2265-70. PMID: 22095816.
      View in: PubMed
    40. Wiskirchen DE, Kuti JL, Nicolau DP. Acute physiology and chronic health evaluation II score is a better predictor of mortality than IBMP-10 in patients with ventilator-associated pneumonia. Surg Infect (Larchmt). 2011 Oct; 12(5):385-90. PMID: 22004437.
      View in: PubMed
    41. Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2012 Jan; 56(1):202-7. PMID: 22006007; PMCID: PMC3256059.
    42. Keel RA, Kuti JL, Sahm DF, Nicolau DP. Pharmacodynamic evaluation of i.v. antimicrobials against Pseudomonas aeruginosa samples collected from U.S. hospitals. Am J Health Syst Pharm. 2011 Sep 1; 68(17):1619-25. PMID: 21856807.
      View in: PubMed
    43. Housman ST, Kuti JL, Nicolau DP. Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia. Clin Chest Med. 2011 Sep; 32(3):439-50. PMID: 21867814.
      View in: PubMed
    44. Wiskirchen DE, Shepard A, Kuti JL, Nicolau DP. Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemother. 2011 Sep; 55(9):4170-5. PMID: 21709078; PMCID: PMC3165366.
    45. Sutherland CA, Nicolau DP, Kuti JL. Development of an HPLC method for the determination of anidulafungin in human plasma and saline. J Chromatogr Sci. 2011 May; 49(5):397-400. PMID: 21549032.
      View in: PubMed
    46. Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, Nicolau DP, Kuti JL. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother. 2011 Jul; 55(7):3393-8. PMID: 21518837; PMCID: PMC3122391.
    47. Wiskirchen DE, Koomanachai P, Nicasio AM, Nicolau DP, Kuti JL. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob Agents Chemother. 2011 Apr; 55(4):1420-7. PMID: 21282442; PMCID: PMC3067181.
    48. Koomanachai P, Keel RA, Johnson-Arbor KK, Suecof LA, Nicolau DP, Kuti JL. Linezolid penetration into wound tissue of two diabetic patients before and after hyperbaric oxygen therapy. Undersea Hyperb Med. 2011 Jan-Feb; 38(1):11-6. PMID: 21384759.
      View in: PubMed
    49. Roberts JA, Kwa A, Montakantikul P, Gomersall C, Kuti JL, Nicolau DP. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region. Int J Antimicrob Agents. 2011 Mar; 37(3):225-9. PMID: 21168997.
      View in: PubMed
    50. Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med. 2011 Apr; 37(4):632-8. PMID: 21136037.
      View in: PubMed
    51. Keel RA, Sutherland CA, Aslanzadeh J, Nicolau DP, Kuti JL. Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies. Diagn Microbiol Infect Dis. 2010 Nov; 68(3):326-9. PMID: 20955917.
      View in: PubMed
    52. Bulik CC, Wiskirchen DE, Shepard A, Sutherland CA, Kuti JL, Nicolau DP. Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother. 2010 Dec; 54(12):5209-13. PMID: 20921312; PMCID: PMC2981255.
    53. Kuti EL, Kuti JL. Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections. Expert Opin Drug Metab Toxicol. 2010 Oct; 6(10):1287-300. PMID: 20822479.
      View in: PubMed
    54. Crandon JL, Kuti JL, Nicolau DP. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob Agents Chemother. 2010 Dec; 54(12):5115-9. PMID: 20837760; PMCID: PMC2981287.
    55. Kim A, Nicolau DP, Kuti JL. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses. 2011 Sep; 54(5):e301-12. PMID: 20557463.
      View in: PubMed
    56. Bulik CC, Fauntleroy KA, Jenkins SG, Abuali M, LaBombardi VJ, Nicolau DP, Kuti JL. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol. 2010 Jul; 48(7):2402-6. PMID: 20484603; PMCID: PMC2897473.
    57. Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapy. 2010 May; 30(5):453-62. PMID: 20411997.
      View in: PubMed
    58. Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther. 2010 Apr; 32(4):766-79. PMID: 20435246.
      View in: PubMed
    59. Kuti JL, Nicolau DP. Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: an update to our clinical pathway. J Crit Care. 2010 Mar; 25(1):155-6. PMID: 20189057.
      View in: PubMed
    60. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Mar; 54(3):1111-6. PMID: 20038614; PMCID: PMC2825990.
    61. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2010 Feb; 54(2):804-10. PMID: 19995927; PMCID: PMC2812157.
    62. Eagye KJ, Kuti JL, Sutherland CA, Christensen H, Nicolau DP. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals. Clin Ther. 2009 Nov; 31(11):2678-88. PMID: 20110010.
      View in: PubMed
    63. Kim A, Kuti JL, Nicolau DP. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Clin Ther. 2009 Nov; 31(11):2765-78. PMID: 20110018.
      View in: PubMed
    64. Kontou P, Kuti JL, Nicolau DP. Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae. Am J Emerg Med. 2009 Oct; 27(8):968-74. PMID: 19857416.
      View in: PubMed
    65. Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, Russomanno JH, Shore E, Nicolau DP, Kuti JL. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother. 2009 Dec; 53(12):5102-7. PMID: 19770284; PMCID: PMC2786330.
    66. Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer. 2009 Sep; 53(3):379-85. PMID: 19422028.
      View in: PubMed
    67. Bulik CC, Kuti JL, Nicolau DP. Clostridium difficile infection--not just a burden anymore. Conn Med. 2009 Aug; 73(7):407-11. PMID: 19708320.
      View in: PubMed
    68. Eagye KJ, Kim A, Laohavaleeson S, Kuti JL, Nicolau DP. Surgical site infections: does inadequate antibiotic therapy affect patient outcomes? Surg Infect (Larchmt). 2009 Aug; 10(4):323-31. PMID: 19622027.
      View in: PubMed
    69. Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol. 2009 Aug; 30(8):746-52. PMID: 19583513.
      View in: PubMed
    70. Kuti JL, Nicasio AM, Sutherland CA, Nicolau DP. Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus isolated from patients with ventilator-associated pneumonia at a Connecticut hospital. Conn Med. 2009 Jun-Jul; 73(6):337-40. PMID: 19637663.
      View in: PubMed
    71. Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care. 2010 Mar; 25(1):69-77. PMID: 19427167.
      View in: PubMed
    72. Kuti JL, Shore E, Palter M, Nicolau DP. Tackling empirical antibiotic therapy for ventilator-associated pneumonia in your ICU: guidance for implementing the guidelines. Semin Respir Crit Care Med. 2009 Feb; 30(1):102-15. PMID: 19199192.
      View in: PubMed
    73. Eagye KJ, Nicolau DP, Kuti JL. Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia. Semin Respir Crit Care Med. 2009 Feb; 30(1):116-23. PMID: 19199193.
      View in: PubMed
    74. Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother. 2009 Feb; 43(2):220-7. PMID: 19193582.
      View in: PubMed
    75. Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, Nicolau DP. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2009 Apr; 53(4):1476-81. PMID: 19188394; PMCID: PMC2663089.
    76. Nicasio AM, Tessier PR, Nicolau DP, Knauft RF, Russomanno J, Shore E, Kuti JL. Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrob Agents Chemother. 2009 Mar; 53(3):1218-20. PMID: 19114675; PMCID: PMC2650581.
    77. Koomanachai P, Crandon JL, Kuti JL, Nicolau DP. Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program. Int J Antimicrob Agents. 2009 Apr; 33(4):348-53. PMID: 19091515.
      View in: PubMed
    78. Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy. 2008 Dec; 28(12):1471-82. PMID: 19025428.
      View in: PubMed
    79. Laohavaleeson S, Lolans K, Quinn JP, Kuti JL, Nicolau DP. Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime/ceftazidime susceptibility profiles. Infect Drug Resist. 2008; 1:51-5. PMID: 21694880; PMCID: PMC3108718.
    80. Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP. In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob Agents Chemother. 2008 Nov; 52(11):3941-6. PMID: 18779352; PMCID: PMC2573116.
    81. Nicasio AM, Kuti JL, Aslanzadeh J, Nicolau DP. Influence of automated screening and confirmation of extended-spectrum beta-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics. J Med Microbiol. 2008 Sep; 57(Pt 9):1147-51. PMID: 18719186.
      View in: PubMed
    82. Kim SW, Kuti JL, Nicolau DP. Inhaled antimicrobial therapies for respiratory infections. Curr Infect Dis Rep. 2008 Mar; 10(1):29-36. PMID: 18377812.
      View in: PubMed
    83. Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrug-resistant gram-negative bacilli in North America. Pharmacotherapy. 2008 Feb; 28(2):235-49. PMID: 18225969.
      View in: PubMed
    84. Kuti JL, Dowzicky M, Nicolau DP. Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections. Surg Infect (Larchmt). 2008 Feb; 9(1):57-66. PMID: 18363469.
      View in: PubMed
    85. Fallon RM, Kuti JL, Doern GV, Girotto JE, Nicolau DP. Pharmacodynamic target attainment of oral beta-lactams for the empiric treatment of acute otitis media in children. Paediatr Drugs. 2008; 10(5):329-35. PMID: 18754699.
      View in: PubMed
    86. Pichichero ME, Doern GV, Kuti JL, Nicolau DP. Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children. Paediatr Drugs. 2008; 10(6):391-7. PMID: 18998749.
      View in: PubMed
    87. Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy. 2007 Nov; 27(11):1490-7. PMID: 17963458.
      View in: PubMed
    88. Berenholtz SM, Pronovost PJ, Ngo K, Barie PS, Hitt J, Kuti JL, Septimus E, Lawler N, Schilling L, Dorman T. Developing quality measures for sepsis care in the ICU. Jt Comm J Qual Patient Saf. 2007 Sep; 33(9):559-68. PMID: 17915530.
      View in: PubMed
    89. Wang H, Zhang B, Ni Y, Kuti JL, Chen B, Chen M, Nicolau DP. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. Int J Antimicrob Agents. 2007 Nov; 30(5):452-7. PMID: 17646088.
      View in: PubMed
    90. Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin Investig Drugs. 2007 May; 16(5):717-33. PMID: 17461743.
      View in: PubMed
    91. Eagye KJ, Kuti JL, Dowzicky M, Nicolau DP. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. Clin Ther. 2007 May; 29(5):889-99. PMID: 17697907.
      View in: PubMed
    92. Nicasio AM, Quintiliani R, DeRyke CA, Kuti JL, Nicolau DP. Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem. Ann Pharmacother. 2007 Jun; 41(6):1077-81. PMID: 17472997.
      View in: PubMed
    93. Eagye KJ, Kuti JL, Nicolau DP. Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling. Surg Infect (Larchmt). 2007 Apr; 8(2):215-26. PMID: 17437367.
      View in: PubMed
    94. Kiffer CR, Kuti JL, Mendes CM, Oplustil CP, Amarante JB, Biancalana ML, Xavier N, Nicolau DP. A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit. Braz J Infect Dis. 2007 Apr; 11(2):183-5. PMID: 17625756.
      View in: PubMed
    95. DeRyke CA, Kuti JL, Nicolau DP. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):337-44. PMID: 17350206.
      View in: PubMed
    96. Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Expert Opin Investig Drugs. 2007 Mar; 16(3):347-57. PMID: 17302529.
      View in: PubMed
    97. DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy. 2007 Mar; 27(3):333-42. PMID: 17316145.
      View in: PubMed
    98. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007 May; 51(5):1725-30. PMID: 17307978; PMCID: PMC1855547.
    99. Kioumis IP, Kuti JL, Nicolau DP. Intra-abdominal infections: considerations for the use of the carbapenems. Expert Opin Pharmacother. 2007 Feb; 8(2):167-82. PMID: 17257087.
      View in: PubMed
    100. DeRyke CA, Sutherland C, Zhang B, Nicolau DP, Kuti JL. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob Agents Chemother. 2006 Nov; 50(11):3529-34. PMID: 17065618; PMCID: PMC1635189.
    101. Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals. Int J Antimicrob Agents. 2006 Nov; 28(5):433-8. PMID: 17046212.
      View in: PubMed
    102. Lee SY, Kuti JL, Nicolau DP. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. J Infect. 2007 May; 54(5):463-8. PMID: 17067681.
      View in: PubMed
    103. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006 Nov; 27(11):1226-32. PMID: 17080381.
      View in: PubMed
    104. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol. 2006 Oct; 46(10):1171-8. PMID: 16988206.
      View in: PubMed
    105. Sun HK, Nicolau DP, Kuti JL. Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae. Chest. 2006 Sep; 130(3):807-14. PMID: 16963679.
      View in: PubMed
    106. Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, Dana A. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2006 Nov; 50(11):3556-61. PMID: 16940077; PMCID: PMC1635208.
    107. Kiffer CR, Kuti JL, Eagye KJ, Mendes C, Nicolau DP. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil. Int J Antimicrob Agents. 2006 Oct; 28(4):340-4. PMID: 16930951.
      View in: PubMed
    108. Lee SY, Fan HW, Kuti JL, Nicolau DP. Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opin Pharmacother. 2006 Jul; 7(10):1381-97. PMID: 16805723.
      View in: PubMed
    109. Kuti JL, Ong C, Lo M, Melnick D, Soto N, Nicolau DP. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents. 2006 Jul; 28(1):62-8. PMID: 16759839.
      View in: PubMed
    110. DeRyke CA, Kuti JL, Mansfield D, Dana A, Nicolau DP. Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection. Am J Health Syst Pharm. 2006 Apr 15; 63(8):750-5. PMID: 16595817.
      View in: PubMed
    111. Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA program. Paediatr Drugs. 2006; 8(2):131-8. PMID: 16608373.
      View in: PubMed
    112. Lee SY, Kuti JL, Nicolau DP. Polymyxins: older antibiotics for a new threat. Conn Med. 2006 Jan; 70(1):25-8. PMID: 16479873.
      View in: PubMed
    113. Du X, Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. J Clin Pharmacol. 2006 Jan; 46(1):69-75. PMID: 16397286.
      View in: PubMed
    114. DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs. 2006; 66(1):1-14. PMID: 16398565.
      View in: PubMed
    115. Kuti JL, Nicolau DP. Making the most of surveillance studies: summary of the OPTAMA Program. Diagn Microbiol Infect Dis. 2005 Dec; 53(4):281-7. PMID: 16360552.
      View in: PubMed
    116. Ellis JM, Kuti JL, Nicolau DP. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program. Clin Ther. 2005 Nov; 27(11):1820-30. PMID: 16368453.
      View in: PubMed
    117. Gillespie EL, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials: treatment optimisation. Expert Opin Drug Metab Toxicol. 2005 Oct; 1(3):351-61. PMID: 16863448.
      View in: PubMed
    118. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infect. 2005 Oct; 51(3):211-7. PMID: 16230218.
      View in: PubMed
    119. Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. Crit Care Med. 2005 Oct; 33(10):2222-7. PMID: 16215374.
      View in: PubMed
    120. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother. 2005 Aug; 56(2):388-95. PMID: 16002420.
      View in: PubMed
    121. Kuti JL, Horowitz S, Nightingale CH, Nicolau DP. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. Pharmacotherapy. 2005 Jul; 25(7):935-41. PMID: 16006272.
      View in: PubMed
    122. Maglio D, Kuti JL, Nicolau DP. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program. Clin Ther. 2005 Jul; 27(7):1032-42. PMID: 16154482.
      View in: PubMed
    123. Kuti JL, Nicolau DP. Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. Chemotherapy. 2005 Jul; 51(4):211-6. PMID: 15985760.
      View in: PubMed
    124. DeRyke CA, Kuti JL, Nicolau DP. Questioning the paradigm: monotherapy vs combination antimicrobial therapy for treatment of Pseudomonas aeruginosa. Conn Med. 2005 May; 69(5):271-5. PMID: 16114642.
      View in: PubMed
    125. Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP. The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion. Intensive Crit Care Nurs. 2005 Apr; 21(2):87-93. PMID: 15778072.
      View in: PubMed
    126. Gillespie EL, Kuti JL, Nicolau DP. When "S" does not mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection. Conn Med. 2005 Apr; 69(4):203-10. PMID: 15926635.
      View in: PubMed
    127. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt). 2005; 6(3):283-95. PMID: 16201938.
      View in: PubMed
    128. Kotapati S, Kuti JL, Nicolau DP. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program. Surg Infect (Larchmt). 2005; 6(3):297-304. PMID: 16201939.
      View in: PubMed
    129. Ong CT, Kuti JL, Nicolau DP. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program. Surg Infect (Larchmt). 2005; 6(4):419-26. PMID: 16433606.
      View in: PubMed
    130. Masterton RG, Kuti JL, Turner PJ, Nicolau DP. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother. 2005 Jan; 55(1):71-7. PMID: 15574471.
      View in: PubMed
    131. Kuti JL, Moss KM, Nicolau DP, Knauft RF. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy. 2004 Nov; 24(11):1641-5. PMID: 15537567.
      View in: PubMed
    132. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther. 2004 Aug; 26(8):1187-98. PMID: 15476901.
      View in: PubMed
    133. Kuti JL, Nightingale CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob Agents Chemother. 2004 Jul; 48(7):2464-70. PMID: 15215095; PMCID: PMC434188.
    134. Kotapati S, Nicolau DP, Nightingale CH, Kuti JL. Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm. 2004 Jun 15; 61(12):1264-70. PMID: 15259757.
      View in: PubMed
    135. Kiffer CR, Mendes C, Kuti JL, Nicolau DP. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002. Diagn Microbiol Infect Dis. 2004 Jun; 49(2):109-16. PMID: 15183860.
      View in: PubMed
    136. Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther. 2004 Apr; 26(4):493-501. PMID: 15189746.
      View in: PubMed
    137. Kuti JL, Florea NR, Nightingale CH, Nicolau DP. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Pharmacotherapy. 2004 Jan; 24(1):8-15. PMID: 14740783.
      View in: PubMed
    138. Ong CT, Kuti JL, Nightingale CH, Nicolau DP. Emerging Pseudomonas aeruginosa resistance: implications in clinical practice. Conn Med. 2004 Jan; 68(1):11-5. PMID: 14752913.
      View in: PubMed
    139. Kuti JL, Kotapati S, Williams P, Capitano B, Nightingale CH, Nicolau DP. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics. 2004; 22(5):301-10. PMID: 15061680.
      View in: PubMed
    140. Florea NR, Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study. Am J Health Syst Pharm. 2003 Nov 15; 60(22):2321-7. PMID: 14652981.
      View in: PubMed
    141. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol. 2003 Oct; 43(10):1116-23. PMID: 14517194.
      View in: PubMed
    142. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Role of pharmacodynamics in designing dosage regimens for beta-lactams. Conn Med. 2003 May; 67(5):265-8. PMID: 12802841.
      View in: PubMed
    143. Kuti JL, Maglio D, Nightingale CH, Nicolau DP. Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm. 2003 Mar 15; 60(6):565-8. PMID: 12659058.
      View in: PubMed
    144. Florea NR, Kuti JL, Nightingale CH, Nicolau DP. Treatment of Clostridium difficile-associated disease (CDAD). Conn Med. 2003 Mar; 67(3):153-5. PMID: 12687790.
      View in: PubMed
    145. Kuti J. Antibiotic treatment of catheter-related bacteremia in the hemodialysis patient. Conn Med. 2003 Feb; 67(2):85-8. PMID: 12664836.
      View in: PubMed
    146. Kuti JL, Le TN, Nightingale CH, Nicolau DP, Quintiliani R. Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral. Am J Health Syst Pharm. 2002 Nov 15; 59(22):2209-15. PMID: 12455304.
      View in: PubMed
    147. Kuti JL, Nightingale CH, Quintiliani R, Nicolau D. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis. 2002 Sep; 44(1):51-7. PMID: 12376031.
      View in: PubMed
    148. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy. 2002 Apr; 22(4):471-83. PMID: 11939682.
      View in: PubMed
    149. Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics. 2002; 20(8):513-28. PMID: 12109917.
      View in: PubMed
    Kuti's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _